紧接是次收购事项日期前12个月内，Redwood以代价总额约38,547,000港元(不包括交易成本)收购合共 715,000股迅策股份，即约每股迅策股份53.91港元。该等收购事项後，集团持有合共771,900股迅策股 份，占于本公告日期迅策已发行股份总数约0.24%。 格隆汇2月11日丨金涌投资(01328.HK)公告，于2026年2月11日，公司全资附属公司Redwood通过于联交 所进行市场上交易以代价总额约3,868,000港元(不包括交易成本)进一步收购56,900股迅策股份，即约每 股迅策股份67.98港元。 ...

格隆汇2月11日丨祈福生活服务(03686.HK)公告，于2026年2月11日，集团通过动用部分白银出售事项所 得款项透过该银行下达指令购买约150,000安士已分配银条(即白银投资)，对价约为9810万港元(即人民 币8710万元)，而有关指令已于同日进行配对。白银投资预期将于2026年2月13日完成，而上述对价预期 将由集团于结算时以现金支付。 ...

Core Viewpoint - Shengda Resources (000603.SZ) is currently in the trial production phase at the Honglin Mining Caiyuanzi Copper-Gold Mine, with specific production metrics and regulatory compliance being highlighted [1] Group 1: Production Metrics - The average gold metal grade of the industrial ore body at the Honglin Mining Caiyuanzi Copper-Gold Mine is 2.82 grams per ton [1] - The average copper metal grade is 0.48% [1] - The reported production scale is 396,000 tons per year [1] Group 2: Regulatory Compliance - Honglin Mining is operating in accordance with national regulations and legal requirements for trial production [1] - The company is in the process of obtaining a safety production license, which is necessary for formal production [1] - Official production data will be confirmed after the safety production license is obtained and formal production begins [1]

Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) maintains a stable annual R&D investment of approximately 250-280 million yuan, with a shift in focus towards raw materials and CDMO R&D while decreasing investment in generic drug formulations [1] Group 1: R&D Investment - The company plans to keep its overall R&D investment steady at around 250-280 million yuan each year [1] - There is an increasing proportion of R&D investment allocated to raw materials and CDMO, while the investment in generic drug formulations is gradually declining [1] Group 2: Sales Expenses - The sales expenses for the formulation business are growing rapidly due to its fast development [1] - The company is enhancing its marketing management through the establishment of a digital system [1]

Core Viewpoint - Semiconductor manufacturer GlobalFoundries (GFS.US) saw a pre-market increase of nearly 6%, reaching $44.4, following its fourth-quarter earnings report which exceeded analyst expectations [1] Financial Performance - For the fourth quarter of last year, the company reported revenue of $1.83 billion, slightly above the analyst forecast of $1.8 billion [1] - The adjusted earnings per share (EPS) were $0.55, surpassing the analyst expectation of $0.47 [1] Future Outlook - For the first quarter of this year, the company expects revenue to be between $1.6 billion and $1.65 billion, with adjusted EPS projected between $0.30 and $0.40 [1] - Analysts had anticipated revenue of $1.61 billion and an adjusted EPS of $0.35 [1] Shareholder Returns - The company's board approved a stock buyback plan of up to $500 million [1]

格隆汇2月11日丨中国铁建(01186.HK)宣布，经公司控股股东中国铁道建筑集团有限公司推荐，并经公 司董事会提名委员会审议通过，董事会同意提名裴岷山为公司执行董事候选人，任期自股东会通过之日 起，与公司第六届董事会任期相同。裴先生之委任为公司执行董事尚需经公司股东(「股东」)于公司股 东会审议通过。经董事会提名委员会审议通过，董事会决议聘任裴岷山为公司总裁，任期自董事会通过 之日起，与公司现任高级管理人员任期相同。 ...

| 股份代號: | 06865 | | --- | --- | | 上市法國名稱: | 福萊特玻璃集團股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 11/01/2026 - 11/02/2026 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | (請參閱上述*註 有投票權股期(日/月/ 份權益 | | | | | | | 份百分比 年) | | | CS20260211E00106 | 242,000(L HKD 10.9850 Invesco Capital 1101(L) | | | 22,280,245(L) | 5.04(L)06/02/2026 | | | Management LLC | | | | | 格隆汇2月11日丨根据联交所最新权益披露资料显示，2026年2月6日，福莱特玻璃(06865.HK)获Invesco Capital Man ...

Group 1 - Morgan Stanley increased its stake in Tianqi Lithium (09696.HK) by purchasing 647,000 shares at an average price of HKD 42.9015 per share, amounting to approximately HKD 27.76 million [1] - Following the purchase, Morgan Stanley's total holdings in Tianqi Lithium rose to 8.729 million shares, increasing its ownership percentage from 4.92% to 5.31% [1][2]

格隆汇2月11日丨亿腾嘉和(06998.HK)公告，2月11日耗资1,450港元回购500股。 ...